

onco
invent



Results from the 3rd Quarter 2021

Jan A. Alfheim
CEO

Agenda

1. Welcome to the 3rd Quarter 2021 presentation
2. Results from the 3rd Quarter
3. Financials
4. Q&A


Highlights from Q3 2021

- **Recruitment of colorectal cancer patients to the RAD-18-002 phase 1 trial completed, phase 2a amendment filed in Norway and Sweden.**
- **Advancement of Radspherin[®] to fourth dose level cohort in ongoing RAD-18-001 phase 1 trial in ovarian cancer patients**
- **Oncoinvent strengthens senior management team**

Radspherin[®] RAD-18-002 study

Treatment of Peritoneal Carcinomatosis in colorectal cancer patients


- 8th of September recruitment of RAD-18-002 was completed and 29th of September Safety Review Committee confirmed 7 MBq dose level as clinically relevant dose
- 9 of patients dosed at 7 MBq will reach 9-12 month follow-up time point in January to June of 2022.
- Due to the acceptable recruitment rate during the phase 1 study, Oncoinvent is planning to retain same number of sites in Phase 2A, Uppsala, Sweden and Radium Hospital in Oslo



Radspherin[®] RAD-18-001 study

Treatment of Peritoneal Carcinomatosis in ovarian cancer patients

- 2nd of September recruitment of the 4 MBq cohort was completed and 24th of September Safety Review Committee concluded that it was safe to move to 7 MBq dose level
- To increase the recruitment rate for the upcoming phase 2A study, Oncoinvent is planning to increase the number of sites beyond Leuven Belgium and Radium Hospital in Oslo



Clinical and Regulatory Teams strengthened

- Anne-Kirsti Aksnes joins Oncoinvent as VP Clinical Operations in August
 - Clinical development of the most successful commercial radiopharmaceutical – Xofigo
 - Targovax, Algeta, GE Healthcare
- Kari Myren joins Oncoinvent as CMO in October
 - Medical Doctor by training, strong clinical background with specialty training in surgery
 - Novartis, Roche Diagnostics, Photocure
- Stian Brekke joins Oncoinvent as Head of Regulatory Affairs in October
 - 15 years experience in leading regulatory submissions to various competent authorities, including marketing authorisation applications, orphan drug designation applications, variation applications, clinical trial application
 - Smerud, Pharmaq



Financials



Q3-2021 Financial results

KEY FIGURES AMOUNTS IN NOK	3rd QUARTER		YTD		FULL YEAR
	2021	2020	2021	2020	2020
TOTAL REVENUES AND OTHER INCOME	3 290 112	1 636 166	4 562 906	4 656 832	10 377 166
Payroll and related expenses	9 906 971	8 018 738	25 850 207	20 837 658	31 401 987
Other operating expenses	13 348 940	6 416 934	33 835 312	22 403 788	34 395 890
TOTAL OPERATING EXPENSES	23 255 911	14 435 671	59 685 519	43 241 446	65 797 877
EBITDA	- 19 965 799	- 12 799 505	- 55 122 613	- 38 584 614	- 55 420 711
Depreciation and amortization	- 1 181 735	- 1 091 326	- 3 508 241	- 3 589 361	- 4 830 452
EBIT	- 21 147 534	- 13 890 831	- 58 630 854	- 42 173 975	- 60 251 163
Finance cost and other income	80 391	- 109 373	70 615	- 152 739	- 1 031 396
NET PROFIT(LOSS) FOR THE PERIOD	- 21 227 925	- 13 781 458	- 58 701 469	- 42 021 236	- 59 219 767
Net Proceeds from equity issue	252 465 334	336	253 157 692	49 525 224	49 568 974
Cash and cash equivalents, end of period	316 905 446	124 732 425	316 905 446	124 732 425	113 297 444
Total number of shares, beginning of period	14 314 639	14 306 904	14 310 264	14 306 904	13 190 411
Total number of shares, end of period	19 387 895	14 310 264	19 387 895	14 310 264	14 314 639

- Q3 EBITDA results of minus NOK 20 mill
 - Operating expenses NOK 23,3 mill
 - Revenue of NOK 3,3 mill
- YTD EBITDA results of minus NOK 55,1 mill
 - Operating expenses of NOK 59,7 mill.
- Cash balance of NOK 316,9 mill.



Q & A



onco
invent